ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,180.74
0.00%
Dow Jones
38,852.27
0.00%
US Dollar vs MXN
16.86475
-0.12%
Brent Oil
82.885
-0.71%
Bitcoin
63,611.88
0.71%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Inozyme Pharma Inc (INZY)

  7. Inozyme Pharma Inc (INZY) Noticias

INZY Inozyme Pharma Inc

4.88
0.00 (0.00%)
Pre Mercado
Última actualización: 06:00:11
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Inozyme Pharma Inc INZY NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 4.88 06:00:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.88
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
07/5/202407:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202407:32EDGAR2Form 8-K - Current report
07/5/202407:30GLOBEInozyme Pharma Reports First Quarter 2024 Financial Results..
03/5/202407:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
08/4/202405:30GLOBEInozyme Pharma Announces Positive Topline Data from Ongoing..
05/4/202417:00GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
02/4/202407:30GLOBEInozyme Pharma to Participate at the 23rd Annual Needham..
26/3/202407:30GLOBEInozyme Pharma to Report Topline Data from Ongoing Phase 1/2..
12/3/202407:30GLOBEInozyme Pharma Reports Full Year 2023 Financial Results and..
26/2/202407:30GLOBEInozyme Pharma to Participate in the TD Cowen 44th Annual..
14/2/202407:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202420:06EDGAR2Form SC 13D/A - General statement of acquisition of..
06/2/202407:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/12/202307:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
15/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
09/11/202307:30GLOBEInozyme Pharma to Participate in Upcoming Investor..
07/11/202315:07EDGAR2Form S-3 - Registration statement under Securities Act of..
07/11/202307:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202307:31EDGAR2Form 8-K - Current report
07/11/202307:30GLOBEInozyme Pharma Reports Third Quarter 2023 Financial Results..
03/11/202315:15GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
26/10/202307:30GLOBEInozyme Pharma Announces Presentation at the American..
10/10/202307:30GLOBEInozyme Pharma Highlights Inclusion of Generalized Arterial..
06/10/202307:30GLOBEInozyme Pharma Announces Three Poster Presentations at the..
03/10/202315:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/9/202315:12EDGAR2Form 8-K - Current report
26/9/202306:30GLOBEInozyme Pharma Announces Positive Interim Data from Ongoing..
20/9/202307:30GLOBEInozyme Pharma to Host Virtual Investor and Analyst Event on..
06/9/202307:30GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
05/9/202307:30GLOBEInozyme Pharma to Present at the H.C. Wainwright 25th Annual..
11/8/202315:08EDGAR2Form SC 13D/A - General statement of acquisition of..
08/8/202308:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202307:37EDGAR2Form 8-K - Current report
08/8/202307:30GLOBEInozyme Pharma Reports Second Quarter 2023 Financial Results..
07/8/202320:58EDGAR2Form SC 13D/A - General statement of acquisition of..
03/8/202319:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/8/202315:01GLOBEInozyme Pharma Reports Inducement Grants Under Nasdaq..
01/8/202315:01GLOBEInozyme Pharma, Inc. Announces Closing of Public Offering of..
28/7/202316:19EDGAR2Form 8-K - Current report
28/7/202316:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/7/202322:20GLOBEInozyme Pharma, Inc. Announces Pricing of Public Offering of..
27/7/202316:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/7/202315:33GLOBEInozyme Pharma, Inc. Announces Proposed Offering of Common..
26/7/202306:42EDGAR2Form 8-K - Current report
26/7/202306:30GLOBEInozyme Pharma Announces Updates on Global Development..
19/7/202307:30GLOBEInozyme Pharma to Provide ENPP1 Deficiency Program Update on..
27/6/202307:30GLOBEInozyme Pharma Announces Dosing of First Infant with ENPP1..
02/6/202306:30GLOBEInozyme Pharma to Present at the Jefferies Healthcare..
09/5/202307:30GLOBEInozyme Pharma Reports First Quarter 2023 Financial Results..

Su Consulta Reciente

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados